648934-20-7

Basic information

• Product Name: 1H-Pyrrole-1-carboxylic acid, 2,5-dihydro-2-[[(methylsulfonyl)oxy]methyl]-, phenylmethyl ester, (2S)-
• CAS NO: 648934-20-7
• Molecular Formula: C14H17NO5S
• Molecular Weight: 311.359
• Mol File: 648934-20-7.mol

Chemical Properties

• CAS DataBase Reference: 1H-Pyrrole-1-carboxylic acid, 2,5-dihydro-2-[[(methylsulfonyl)oxy]methyl]-, phenylmethyl ester, (2S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrrole-1-carboxylic acid, 2,5-dihydro-2-[[(methylsulfonyl)oxy]methyl]-, phenylmethyl ester, (2S)-(648934-20-7)
• EPA Substance Registry System: 1H-Pyrrole-1-carboxylic acid, 2,5-dihydro-2-[[(methylsulfonyl)oxy]methyl]-, phenylmethyl ester, (2S)-(648934-20-7)

Safety Data

• Hazardous Substances Data: 648934-20-7(Hazardous Substances Data)

Usage

Molecular weight

331.4 This is the mass of a molecule of Smofils, measured in atomic mass units (amu).

Appearance

Clear, pale yellow oil This describes the physical appearance of Smofils, which is a liquid with a pale yellow color.

Solubility

Slightly soluble in water, soluble in organic solvents This indicates that Smofils is not very soluble in water but dissolves easily in organic solvents such as ethanol or acetone.

Biological activity

Smofils is used as a pharmaceutical ingredient in the preparation of lipid emulsions for intravenous nutrition therapy. It is often used in combination with other vitamins and minerals to provide a complete source of nutrition for patients who are unable to consume food orally. Smofils is known for its ability to emulsify fats and promote their absorption in the body, making it a valuable component in the treatment of malnutrition and other conditions requiring intravenous nutrition therapy. This describes the specific uses and benefits of Smofils in a medical context.

Upstream product

• 5211-24-5 (2S)-2,5-dihydro-1H-pyrrole-1,2-dicarboxylic acid 2-methyl 1-(phenylmethyl) ester 
• 124-63-0 methanesulfonyl chloride 
• 648934-18-3 (S)-2-hydroxymethyl-2,5-dihydropyrrole-1-carboxylic acid benzyl ester 

Downstream Products

• 648934-49-0 (3aR,6S,6aS)-1-[(2S)-2-(4-tert-butylbenzoylamino)-4-methylpentanoyl]-6-hydroxyhexahydropyrrolo[3,2-c]pyrazole-2,4-dicarboxylic acid 4-benzyl ester 2-tert-butyl ester 
• 648934-51-4 (3aR,6S,6aS)-4-benzoyl-1-[(2S)-2-(4-tert-butylbenzoylamino)-4-methylpentanoyl]-6-hydroxyhexahydropyrrolo[3,2-c]pyrazole-2-carboxylic acid tert-butyl ester 
• 648934-56-9 (3aR,6aS)-4-benzoyl-1-[(2S)-2-(4-tert-butylbenzoylamino)-4-methylpentanoyl]-6-oxo-hexahydropyrrolo[3,2-c]pyrazole-2-carboxylic acid tert-butyl ester 
• 648934-45-6 (2S)-2-{N-tert-butoxycarbonyl-N'-[(2S)-2-(4-tert-butylbenzoylamino)-4-methylpentanoyl]-hydrazinomethyl}-2,5-dihydropyrrole-1-carboxylic acid benzyl ester 
• 648934-38-7 (2S)-2-[N'-((2S)-2-allyloxycarbonylamino-4-methylpentanoyl)-N-tert-butoxycarbonylhydrazinomethyl]-2,5-dihydropyrrole-1-carboxylic acid benzyl ester 
• 648934-54-7 (3aR,6S,6aS)-1-[(2S)-2-(4-tert-butylbenzoylamino)-4-methylpentanoyl]-6-hydroxyhexahydropyrrolo[3,2-c]pyrazole-2-carboxylic acid tert-butyl ester 
• 648934-43-4 (2S)-2-[N'-((2S)-2-amino-4-methylpentanoyl)-N-tert-butoxycarbonylhydrazinomethyl]-2,5-dihydropyrrole-1-carboxylic acid benzyl ester 
• 648934-32-1 (S)-2-(N-tert-butoxycarbonyl-N'-allyloxycarbonylhydrazinomethyl)-2,5-dihydropyrrole-1-carboxylic acid benzyl ester 
• 648934-27-4 (S)-2-(N'-allyloxycarbonylhydrazinomethyl)-2,5-dihydropyrrole-1-carboxylic acid benzyl ester 
• 648934-35-4 (S)-2-(N-tert-butoxycarbonylhydrazinomethyl)-2,5-dihydropyrrole-1-carboxylic acid benzyl ester 
• 648934-24-1 (S)-2-aminomethyl-2,5-dihydropyrrole-1-carboxylic acid benzyl ester 
• 648934-22-9 (S)-2-azidomethyl-2,5-dihydropyrrole-1-carboxylic acid benzyl ester 

Relevant articles and documents

cis-6-oxo-hexahydro-2-oxa-1,4-diazapentalene and cis-6-oxo- hexahydropyrrolo[3,2-c]pyrazole based scaffolds: Design rationale, synthesis and cysteinyl proteinase inhibition

The 5,5-bicycles cis-6-oxo-hexahydro-2-oxa-1,4-diazapentalene 3 and cis-6-oxo-hexahydropyrrolo[3,2-c]pyrazole 4 were designed as rotationally restricted templates towards the preparation of inhibitors of CAC1 cysteinyl proteinases. The design strategy was

BIOLOGICALLY ACTIVE COMPOUNDS

Compounds of general formula (I) wherein: Z = CR3R4, where R3 and R4 are independently chosen from CO-7-alkyl P1 = CR5R6, P2 = O, CR7R8/sup